

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported): November 1, 2016

**Palatin Technologies, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**001-15543**

(Commission  
File Number)

**95-4078884**

(IRS employer  
identification number)

**4B Cedar Brook Drive, Cranbury, NJ**

(Address of principal executive offices)

**08512**

(Zip Code)

Registrant's telephone number, including area code: **(609) 495-2200**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

## **Item 8.01 Other Events.**

On November 1, 2016, we issued a press release announcing positive top-line results in our Phase 3 clinical trial program of bremelanotide as an on-demand treatment for premenopausal women diagnosed with hypoactive sexual desire disorder, and announcing a teleconference and audio webcast to be held November 2 at 9:00 a.m. Eastern Time, which will include a discussion of top-line results of the Phase 3 bremelanotide efficacy trials. Bremelanotide 1.75 mg met the pre-specified co-primary efficacy endpoints of improvement in desire and decrease in distress associated with low sexual desire as measured using validated patient-report outcome instruments.

We have attached a copy of the press release as exhibit 99.1 to this report, which press release is incorporated by reference herein.

## **Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits:

[99.1](#) Press Release dated November 1, 2016

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PALATIN TECHNOLOGIES,  
INC.

Date: November 1, 2016

By: /s/ Stephen T. Wills  
Stephen T. Wills, CPA, MST  
Executive Vice President,  
Chief Financial Officer and  
Chief Operating Officer

---

## EXHIBIT INDEX

[99.1](#) Press Release dated November 1, 2016

---